Core Insights - Journey Medical Corporation reported revenue of $16.08 million for the quarter ended December 2025, marking an 18.1% year-over-year increase, but fell short of the Zacks Consensus Estimate by 15.68% [1] - The company reported an EPS of -$0.04, which is an improvement compared to $0.08 a year ago, resulting in a positive EPS surprise of 27.27% against the consensus estimate of -$0.06 [1] Revenue Breakdown - Total net product revenue from Accutane was $3.06 million, exceeding the average estimate of $2.77 million, but reflecting a year-over-year decline of 20.9% [4] - Total net product revenue from EmrosiTM was $5 million, significantly lower than the estimated $7.42 million [4] - Total net product revenue from Qbrexza was $5.54 million, also below the estimated $6.97 million, with a year-over-year change of -2.4% [4] Stock Performance - Journey Medical's shares have decreased by 21.7% over the past month, contrasting with a 5% decline in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Journey Medical Corporation reported revenue of $17.63 million for the quarter ended September 2025, reflecting a year-over-year increase of 20.5% [1] - The earnings per share (EPS) was -$0.09, an improvement from -$0.12 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $17.7 million by 0.39%, while the EPS was below the consensus estimate of -$0.08 by 12.5% [1] Financial Performance Metrics - Total net product revenue for Accutane was $2.77 million, which is 30.7% lower than the year-ago figure and below the average estimate of $3.54 million [4] - Total net product revenue for EmrosiTM was reported at $4.88 million, compared to the estimated $6.35 million, indicating a significant shortfall [4] - Total net product revenue for Qbrexza was $7.36 million, slightly exceeding the estimated $6.67 million, but still showing a year-over-year decline of 2.9% [4] Stock Performance - Journey Medical's shares have increased by 25.7% over the past month, outperforming the Zacks S&P 500 composite, which rose by 4.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]